Novartis and Gilead’s CAR-T therapies have been approved in Europe – and the UK’s NICE immediately slapped down the latter, saying it is too expensive for regular NHS use in England and Wales.
Saturday Night Live‘s “Weekend Update” co-hosts Michael Che and Colin Jost had a lot of material to play with after Donald Trump’s first week back in the Oval Office. Jost kicked things ...
The latest decision by NICE ensures that those patients in the third line setting will continue to have access to CAR-T cell therapy. While long-term data was collected, Yescarta has previously ...